Filing Worth Watching: Cynosure Inc: Broadwood Partners Lp Opened Big New Position

Filing Worth Watching: Cynosure Inc: Broadwood Partners Lp Opened Big New Position

The New Broadwood Partners Lp Holding in Cynosure Inc

Broadwood Partners Lp filed with the SEC SC 13G form for Cynosure Inc. The form can be accessed here: 000091957416016678. As reported in Broadwood Partners Lp’s form, the filler as of late owns 5.6% or 1,331,727 shares of the Health Care–company.

Cynosure Inc stake is a new one for the and it was filed because of activity on November 1, 2016. We feel this shows Broadwood Partners Lp’s positive view for the stock.

Cynosure Inc Institutional Sentiment

Latest Security and Exchange filings show 159 investors own Cynosure Inc. The institutional ownership in Q3 2015 is high, at 119.49% of the outstanding shares. This is increased by 7544358 the total institutional shares. 28198783 were the shares owned by these institutional investors. In total 20 funds opened new Cynosure Inc stakes, 62 increased stakes. There were 26 that closed positions and 50 reduced them.

2 managers had the stock in their top Ten. Notable investors are: Drill Craig A, Thomson Horstmann & Bryant Inc, Falcon Point Capital Llc, Insight Capital Research & Management Inc, Broadwood Capital Inc..

Elk Creek Partners Llc is an institutional investor bullish on Cynosure Inc, owning 434676 shares as of Q3 2015 for 1.06% of its portfolio. Falcon Point Capital Llc owns 132822 shares or 1.43% of its portfolio. NY Broadwood Capital Inc have 5.30% of their stock portfolio for 895455 shares. Further, Archon Capital Management Llc reported stake worth 3.77% of its US stock portfolio. The CT Thomson Horstmann & Bryant Inc owns 507928 shares. Cynosure Inc is 1.50% of the manager’s US portfolio.

Business Profile

Cynosure Inc. (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. The Company operates through aesthetic treatment products and services segment. It markets radiofrequency (RF) energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery; gynecology; ear, nose and throat procedures; ophthalmology; oral and maxillofacial surgery; podiatry, and proctology. The Company’s product portfolio utilizes a range of energy sources, including Alexandrite, diode, neodymium-doped yttrium aluminum garnet (Nd: YAG), pulse dye, Q-switched lasers, intense pulsed light and RF technology.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 2.05 in Q2 2016. Its up 0.73, from 1.32 in 2016Q1. The ratio is positive, as 13 funds sold all Cynosure, Inc. shares owned while 43 reduced positions. 43 funds bought stakes while 72 increased positions. They now own 23.16 million shares or 3.96% more from 22.27 million shares in 2016Q1.

Sawgrass Asset Mngmt Ltd Co holds 0.07% of its portfolio in Cynosure, Inc. (NASDAQ:CYNO) for 30,360 shares. Strs Ohio reported 19,400 shares or 0% of all its holdings. Moreover, Metropolitan Life Ins Ny has 0.01% invested in Cynosure, Inc. (NASDAQ:CYNO) for 17,125 shares. Winslow Evans & Crocker accumulated 1,050 shares or 0% of the stock. Thompson Siegel & Walmsley Lc last reported 0.24% of its portfolio in the stock. The Australia-based Macquarie Group Limited has invested 0% in Cynosure, Inc. (NASDAQ:CYNO). Blackrock Japan Limited reported 752 shares or 0% of all its holdings. Qs Ltd Liability Corporation has 6 shares for 0% of their US portfolio. Moreover, Blackrock Institutional Trust Na has 0% invested in Cynosure, Inc. (NASDAQ:CYNO) for 628,008 shares. Goldman Sachs Group accumulated 72,186 shares or 0% of the stock. Granahan Investment Mngmt Inc Ma has 434,472 shares for 0.77% of their US portfolio. Susquehanna International Gru Llp holds 0% or 12,385 shares in its portfolio. Federated Invsts Inc Pa holds 0% or 1,129 shares in its portfolio. Credit Suisse Ag owns 73,930 shares or 0% of their US portfolio. The California-based Insight Capital Rech & Mngmt Inc has invested 2% in Cynosure, Inc. (NASDAQ:CYNO).

Insider Transactions: Since August 11, 2016, the stock had 0 insider buys, and 7 sales for $2.79 million net activity. 4,222 shares were sold by Davin Michael R, worth $224,540. Another trade for 5,834 shares valued at $311,236 was sold by BAKER TIMOTHY W. Delaney Douglas J also sold $108,595 worth of Cynosure, Inc. (NASDAQ:CYNO) on Thursday, August 11. BAREFOOT BRIAN M. had sold 21,000 shares worth $1.08M on Tuesday, August 30.

The stock decreased 4.19% or $1.75 during the last trading session, hitting $40.05. About 600,841 shares traded hands or 53.72% up from the average. Cynosure, Inc. (NASDAQ:CYNO) has declined 3.60% since April 12, 2016 and is downtrending. It has underperformed by 8.58% the S&P500.

Cynosure Inc. develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. The company has a market cap of $961.28 million. The Firm operates through aesthetic treatment services and products segment. It has a 45.49 P/E ratio. It markets radiofrequency (RF) energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery; gynecology; ear, nose and throat procedures; ophthalmology; oral and maxillofacial surgery; podiatry, and proctology.

Cynosure, Inc. (NASDAQ:CYNO) Ratings Coverage

Out of 3 analysts covering Cynosure Inc (NASDAQ:CYNO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $52 is the highest target while $44 is the lowest. The $51 average target is 27.34% above today’s ($40.05) stock price. Cynosure Inc has been the topic of 6 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The company was initiated on Thursday, August 13 by Stifel Nicolaus. The firm has “Buy” rating by Stifel Nicolaus given on Monday, September 14. The rating was maintained by Maxim Group on Tuesday, December 22 with “Buy”. The stock of Cynosure, Inc. (NASDAQ:CYNO) earned “Buy” rating by Aegis Capital on Thursday, November 3. The rating was upgraded by Zacks to “Sell” on Tuesday, August 18. The rating was maintained by Stifel Nicolaus on Tuesday, January 5 with “Buy”.

Another recent and important Cynosure, Inc. (NASDAQ:CYNO) news was published by Prnewswire.com which published an article titled: “Cynosure Announces Record Third-Quarter Revenues; Revenues Increase 36 Percent …” on October 25, 2016.

According to Zacks Investment Research, “Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure’s products incorporate a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag and diode lasers, as well as intense pulsed light.”

CYNO Company Profile

Cynosure Inc. (Cynosure), incorporated on July 10, 1991, develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. The Firm operates through aesthetic treatment services and products segment. The Firm also markets radiofrequency (RF) energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery; gynecology; ear, nose and throat procedures; ophthalmology; oral and maxillofacial surgery; podiatry, and proctology. The Company’s product portfolio utilizes a range of energy sources, including Alexandrite, diode, neodymium-doped yttrium aluminum garnet (Nd: YAG), pulse dye, Q-switched lasers, intense pulsed light and RF technology. It offers single energy source systems, as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. The Company’s products include Elite, SmartLipo, Cellulaze, Cynergy, Accolade, MedLite C6, PicoSure, Icon aesthetic system, Vectus, SculpSure hyperthermic laser treatment and MonaLisa Touch laser.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment